Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258876 | 1.00 | SLC6A9 (0.48) | SLC6A9KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL421721 | 0.90 | CA12 (0.52) | SLC6A9KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL3027243 | 0.85 | SLC6A9 (0.45) | SLC6A9SCN8ASCN10AAKR1C3AKR1C2 | |
| SCHEMBL1105439 | 0.85 | HPGD (0.43) | SLC6A9KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL30951357 | 0.85 | HPGD (0.43) | SLC6A9KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL26488238 | 0.83 | LMNA (0.44) | SLC6A9KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL16503418 | 0.83 | PTGS1 (0.47) | KDM4EALDH1A1CA12CA1CA2 | |
| SCHEMBL31092882 | 0.83 | LMNA (0.44) | SLC6A9KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL422420 | 0.82 | LCK (0.45) | SLC6A9KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL3369693 | 0.82 | CES2 (0.48) | KDM4EALDH1A1HPGDHSD17B10AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2010-07-22 | — | — | US | claimed |
| EP-2170820-A2 | IMPROVED PROCESS OF AMIDE FORMATION | Glaxo Group Limited (GB) | 2010-04-07 | — | — | EP | claimed |
| WO-2008155334-A2 | IMPROVED PROCESS OF AMIDE FORMATION | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | claimed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4299064-A2 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3641748-B1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | CLEVELAND CLINIC FOUND (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2021-06-24 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | US | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147831-A1 | PYRROLIDINE DERIVATIVES HAVING ACTIVITY AT THE GLYT1 TRANSPORTER | GLAXO GROUP LIMITED (GB) | 2007-12-27 | — | — | WO | disclosed |
| EP-1841727-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-10 | — | — | EP | disclosed |
| EP-1838663-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006067423-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067417-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067417-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | SLC5A2, SLC5A1, MAT1A | SLC6A9 285/4885KDM4E 2023/4885USP2 2988/4885 |
| US-20100184996-A1 | PROCESS OF AMIDE FORMATION | ADH1C, ADH5, ADH1A | SLC6A9 2553/4885KDM4E 299/4885USP2 3380/4885 |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | SLC6A9 2853/4885KDM4E 1290/4885USP2 3602/4885 |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | SLC5A2, SLC5A1, MAT1A | SLC6A9 285/4885KDM4E 2023/4885USP2 2988/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | SLC6A9 172/4885KDM4E 270/4885USP2 2634/4885 |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | SLC6A9 2853/4885KDM4E 1290/4885USP2 3602/4885 |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | SLC6A9 2853/4885KDM4E 1290/4885USP2 3602/4885 |
| US-20080070973-A1 | Compounds having activity at the GlyT1 transporter | SLC6A7, SLC6A1, SLC6A4 | SLC6A9 27/4885KDM4E 3350/4885USP2 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.